HomeNewsBusinessReal EstateCOVID-19 impact: Smaller cities to see more demand for warehousing space

COVID-19 impact: Smaller cities to see more demand for warehousing space

Smaller cities such as Ludhiana, Coimbatore, Vapi, Guwahati, Bhubaneshwar, Surat, Lucknow, Patna, Siliguri and Ambala- Rajpura belt are witnessing higher warehousing demand especially from e-commerce players

July 29, 2020 / 14:07 IST
Story continues below Advertisement

Pinkesh Teckwani

The ongoing pandemic has severely impacted several sectors of the economy, including the real estate sector. At a time when the Indian real estate sector has been facing a slowdown, the warehousing segment has emerged as a promising investment opportunity for investors.

Story continues below Advertisement

The segment, since 2017, has garnered the second-highest share in equity investment after office and has exceeded investments in the retail asset by over three times. Office segments witnessed the equity investment at 9.3 billion dollars, followed by warehousing at 6.5 billion dollars and retail at 1.9 billion dollars in the said period.

The momentum of investments has seen a minor setback this year due to the pandemic which has led many deals to be stuck in different stages of transactions and are likely to get completed at the onset of normality.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show